Kailera announces $600m Series B led by Bain Capital Private Equity
The financing backs global trials of injectable and oral therapies for obesity.
Kailera Therapeutics announced a $600 million Series B on October 14, 2025, led by new investor Bain Capital Private Equity. The company said the financing would be fully funded at closing.
New investors joined returning backers including Atlas Venture, Bain Capital Life Sciences, RTW Investments and Sirona Capital. The proceeds were intended to advance lead candidate KAI-9531, an injectable GLP-1/GIP dual agonist, into a global Phase 3 obesity program by year-end.
The financing also supports oral GLP-1 candidate KAI-7535 and other injectable and oral programs, extending Kailera’s approach across several mechanisms and routes of administration.
Use of funds
Advance injectable and oral obesity programs into global clinical trials